Annovis Bio Inc. announced on March 25, 2025, its participation in the AD/PD™ 2025 conference, taking place from April 1-5 in Vienna. The company plans to present comprehensive data from its latest Phase 3 Parkinson's disease (PD) and Phase 2/3 Alzheimer's disease (AD) studies. This includes a deeper look into the cognitive response in Parkinson's patients.
For Alzheimer's patients, Annovis will present data on the advantages of buntanetap for APOE4 carriers, addressing a pressing challenge in existing AD therapies. The company will give two presentations and participate in a forum discussion. These presentations will highlight buntanetap's efficacy and safety across both indications.
Maria Maccecchini, Ph.D., CEO of Annovis, stated that the company is at a pivotal moment, having entered late clinical stages for both AD and PD. The presentations will further support that their drug is efficacious and safe across both indications. This event provides an opportunity to share new scientific findings with the broader medical community.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.